We are live on
!
Find out more
HCM
Highline Capital Management Portfolio holdings
AUM
$53.5M
1-Year Est. Return
21.72%
This Fund
S&P 500
This Quarter
Est. Return
+17.09%
1 Year Est. Return
-21.72%
3 Year Est. Return
+197.64%
5 Year Est. Return
+251.63%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$99.2M
(+6.6%)
Cap. Flow
-$90.8M
Cap. Flow
% of AUM
-5.71%
Top 10 Holdings %
Top 10 Hldgs %
54.78%
Holding
46
New
12
Increased
7
Reduced
16
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Take-Two Interactive
TTWO
|
+$62.6M |
| 2 |
Marvell Technology
MRVL
|
+$49M |
| 3 |
Moelis & Co
MC
|
+$46.5M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$40.1M |
| 5 |
PVTL
Pivotal Software, Inc.
PVTL
|
+$39.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Equinix
EQIX
|
+$101M |
| 2 |
ServiceNow
NOW
|
+$78.1M |
| 3 |
CZR
Caesars Entertainment Corporation
CZR
|
+$73.6M |
| 4 |
GRA
W.R. Grace & Co.
GRA
|
+$54.1M |
| 5 |
BERY
Berry Global Group, Inc.
BERY
|
+$31.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.23% |
| 2 | Consumer Discretionary | 25.32% |
| 3 | Materials | 10.25% |
| 4 | Technology | 8.59% |
| 5 | Industrials | 4.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Royal Caribbean
RCL
$78.7B
| $121M | 7.6% |
1,055,250
-23,700
| -2% | -$2.69M |
|
2
IQVIA
IQV
$34.7B
| $108M | 6.81% |
753,596
-232,535
| -24% | -$31M |
|
3
CALL
Las Vegas Sands
LVS
$30.5B
| $96.3M | 6.05% |
+1,580,000
| New | +$93M |
|
4
BioMarin Pharmaceuticals
BMRN
$11.5B
| $94.7M | 5.95% |
1,066,249
+53,130
| +5% | +$4.92M |
|
|
BERY
5
DELISTED
Berry Global Group, Inc.
BERY
| $92.6M | 5.82% |
1,872,331
-663,595
| -26% | -$31.5M |
|
6
Elevance Health
ELV
$81.9B
| $80M | 5.03% |
278,858
-59,206
| -18% | -$17.1M |
|
7
Caesars Entertainment
CZR
$6.1B
| $75.8M | 4.76% |
1,623,745
-663,354
| -29% | -$30.3M |
|
|
GRA
8
DELISTED
W.R. Grace & Co.
GRA
| $73.1M | 4.59% |
936,400
-734,000
| -44% | -$54.1M |
|
9
Commercial Metals
CMC
$7.63B
| $69M | 4.33% |
4,039,008
+786,500
| +24% | +$13M |
|
|
10
Take-Two Interactive
TTWO
$43B
| $61M | 3.83% |
+646,100
| New | +$62.6M |
|
11
Boyd Gaming
BYD
$6.47B
| $59.7M | 3.75% |
2,181,939
+11,000
| +0.5% | +$300K |
|
12
Rio Tinto
RIO
$148B
| $57.6M | 3.62% |
978,557
+316,700
| +48% | +$17.4M |
|
|
13
Marvell Technology
MRVL
$174B
| $52.1M | 3.28% |
+2,621,400
| New | +$49M |
|
|
14
Sarepta Therapeutics
SRPT
$1.66B
| $52M | 3.27% |
436,000
+311,723
| +251% | +$40.1M |
|
15
VICI Properties
VICI
$29.4B
| $46.5M | 2.92% |
2,123,660
-7,600
| -0.4% | -$161K |
|
|
16
Moelis & Co
MC
$4.98B
| $45.2M | 2.84% |
+1,086,935
| New | +$46.5M |
|
17
Pegasystems
PEGA
$4.41B
| $42.5M | 2.67% |
1,306,576
-122,100
| -9% | -$3.6M |
|
18
Ultragenyx Pharmaceutical
RARE
$2.65B
| $42.3M | 2.66% |
610,063
+151,550
| +33% | +$8.66M |
|
|
PVTL
19
DELISTED
Pivotal Software, Inc.
PVTL
| $42.1M | 2.65% |
+2,020,850
| New | +$39.5M |
|
20
PUT
VanEck Semiconductor ETF
SMH
$67.6B
| $40.4M | 2.54% |
+760,000
| New | +$37.6M |
|
|
MTOR
21
DELISTED
MERITOR, Inc.
MTOR
| $38.8M | 2.44% |
1,905,780
-424,400
| -18% | -$8.64M |
|
22
UroGen Pharma
URGN
$2B
| $36.5M | 2.29% |
986,878
+525,200
| +114% | +$22M |
|
|
23
Las Vegas Sands
LVS
$30.5B
| $34.6M | 2.17% |
+566,900
| New | +$33.4M |
|
|
FPAC.U
24
DELISTED
Far Point Acquisition Corporation Units, each consisting of one share of Class A common stock, $0.00
FPAC.U
| $21.6M | 1.36% |
2,076,099
-416,000
| -17% | -$4.26M |
|
25
Moderna
MRNA
$21.5B
| $18.9M | 1.19% |
930,230
-587,712
| -39% | -$10.9M |
|
Similar funds
NHSP
DTIM
BI
MCAI
PCM
FC
AEPIP
SAM
Highline Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Highline Capital Management held 46 positions worth $1.59B, up 6.6% from $1.49B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Highline Capital Management withdrew a net $90.8M in Q1 2019, closing 11 positions and reducing 16 holdings. Its most notable exit was Equinix, an estimated $101M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 30% of assets, up from 30% a quarter earlier, followed by Consumer Discretionary and Materials.
Against the trend, Highline Capital Management opened a new position in Take-Two Interactive worth $61M.
- Highline Capital Management's largest Q1 2019 buy was Take-Two Interactive: 646,100 shares worth $61M.
- Highline Capital Management added most to Sarepta Therapeutics in Q1 2019, an estimated $40.1M increase.
- Highline Capital Management's biggest Q1 2019 reduction was W.R. Grace & Co., cutting an estimated $54.1M.
- Highline Capital Management fully exited Equinix in Q1 2019, selling an estimated $101M.
- Highline Capital Management's ten largest holdings make up 55% of its $1.59B portfolio in Q1 2019.
- Highline Capital Management opened 12 new positions and closed 11 in Q1 2019.
- Highline Capital Management's portfolio value rose 6.6% quarter-over-quarter to $1.59B.
Based on Highline Capital Management's 13F filing for Q1 2019, filed 15 May 2019.